Q4 2024 Earnings Call Transcript February 20, 2025 NICE Ltd. beats earnings expectations. Reported EPS is $3.02, expectations ...

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that ...

Fourth quarter highlights Revenue of $1.020 billion, up 3% year-over-year and when adjusted for foreign exchange* Security and compute revenue represented 69% of ...

Daifuku has maintained a net cash position for the past eight years. From a more long-term standpoint, net debt/EBITDA peaked at 2.95 times in fiscal 2011, when the company acquired Logan Teleflex.

Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, represe ...

We believe EPAM is financially stable, with enough cash and access to debt to keep up the pace of internal innovation and inorganic expansion efforts, fueling future growth. EPAM had cash and cash ...

Q4 2024 Earnings Conference Call February 20, 2025 8:00 AM ETCompany ParticipantsSebastian McCoskrie - Investor ...

Understanding how tax policies affect IP can help your company optimize its strategies and enhance the value of its IP ...

Financing outstandings have strongly increased in 2024 due to the increase of business and to the sharp rise in average ...

Recurring Revenue was $312 million, up 11% year-over-year Remaining performance obligations of $308.6 million, up 29% year-over-year Fourth quarter revenue of $78.1 million, up 9% year-over-year ...

IMAX Corporation (NYSE: IMAX) today reported solid financial results for the fourth quarter and full-year of 2024, ...

Please note that the limited information that follows in this press release is a summary and is not adequate for making an informed investment decision.